Detail Information
Interactor1 | Interactor2 | |
---|---|---|
Symbol | kshv-miR-K12-1-5p | MAF |
miRBase Accession/Entrez ID |
MIMAT0002182 | 4094 |
Organism | Human gammaherpesvirus 8 (Kaposi's sarcoma herpesvirus, KSHV) | Homo sapiens |
Category | miRNA | mRNA |
Alias | - | AYGRP//c-MAF//CCA4//CTRCT21 |
Resource | Symbol | ModificationPosition | Type | Genomic Context | PMID | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
RMBase | MAF |
|
Resource | Symbol | Subcellular Localization | Tissue or Cell Line | PMID | |||
---|---|---|---|---|---|---|---|
RNALocate | MAF |
|
Interactor1: kshv-miR-K12-1-5p | Interactor2: MAF |
---|
Strong-Evidence | Luciferase reporter assay//RT-PCR//Western blot | |
---|---|---|
Weak-Evidence | Microarray | |
Prediction-Evidence | cRep//miRanda//PITA//Targetscan | |
Support Database | RepTar//ViRBase//VIRmiRNA//VmiReg |
[1]PMID | 21152115 | Target region | 3'UTR |
---|---|---|---|
Source | RepTar//ViRBase | Interactor1 expression | None |
Tissue or cell line | 293T cells//HeLa cells | Interactor2 expression | Downregulation |
Description | More studies from recent reports indicate miR-K12-5, miR-K12-9 and miR-K12-10 repression of Bcl-2-associated transcription factor 1, an apoptosis-inducing factor (238), miR-K12-3 reduction of LRRC8D (leucine rich repeat containing 8 family, member D), a leucin-rich type III transmembrane protein involved in proliferation and activation of lymphocytes, NHP2L1 (non-histone chromosome protein 2-like 1) (239), and a transcription factor NFIB (240), miR-K12-1 inhibition of p21 241 and NFkappaB inhibitor IkappaBalpha (242), miR-K12-4-3p suppression of GEMIN8 (239), miR-K12-10a reduction of TWEAKR (243), miR-K12-1, -6, and -11 decrease of MAF (musculoaponeurotic fibrosarcoma oncogene homolog) (244), K12-4-5p targeting retinoblastoma (Rb)-like protein 2 (Rbl2) and miR-K12-5 and -9*suppressing ORF50 mRNA (245,246). |
[2]PMID | 21277611 | Target region | 3'UTR |
---|---|---|---|
Source | RepTar//ViRBase | Interactor1 expression | None |
Tissue or cell line | 293T cells//HeLa cells | Interactor2 expression | Downregulation |
Description | Analysis of the negatively regulated transcripts with the PITA algorithm (Kertesz et al., 2007) led to the identification of the cellular transcription factor MAF (musculoaponeurotic fibrosarcoma oncogene homolog), which was experimentally confirmed to be a direct target of several KSHV-encoded miRNAs. |
[3]PMID | 20080955 | Target region | 3'UTR |
---|---|---|---|
Source | RepTar//ViRBase//VIRmiRNA//VmiReg | Interactor1 expression | None |
Tissue or cell line | 293T cells//HeLa cells | Interactor2 expression | Downregulation |
Description | Site-directed mutagenesis of KSHV miRNA predicted target sites in the MAF 3'UTR abolished silencing (Fig.3D; Supplemental Fig.2D), confirming that miR-K12-1, miR-K12-6-5p, and miR-K12-11 regulate MAF by interacting with the 3'UTR. |
[4]PMID | 21616184 | Target region | 3'UTR |
---|---|---|---|
Source | RepTar//ViRBase//VIRmiRNA//VmiReg | Interactor1 expression | None |
Tissue or cell line | 293T cells//HeLa cells | Interactor2 expression | Downregulation |
Description | Currently, the validated targets of KSHV miRNAs (Table 1) represent a collection of genes identified by unbiased methods or chosen by previously identified functions.Table 1 KSHVmiRNA validated targets. All targets have been validated using ectopic expression of miRNAs to demonstrate that a luciferase reporter or ectopic reporter are repressed. Additional validations include(1) exogenous reporters have been mutated to disrupt targeting by a ectopic miRNA,(2) ectopic miRNA suppresses endogenous target mRNA and/or protein levels,(3) de novo infection with KSHV represses endogenous target expression,(4) miRNA inhibitors and/or mutant virus display derepression of endogenous target mRNA and/or protein levels, and(5) repression of miRNA target is observed in KSHV clinical samples. |